Aevi Genomic Medicine Moves Forward to Phase 2 of ADHD Clinical Trials


In Pennsylvania, Aevi Genomic Medicine is starting Phase 2 in its clinical trial of AEVI-001 to treat ADHD and other neurological diseases including Autism Spectrum Disorder, Bipolar Disorder, and Schizophrenia. Patients with the specific genetic subset and mutated gene CNTN4, so far had a 90% response rate to the AEVI-001 treatment. About 10% of the pediatric ADHD patients have the 9-Gene subset and about 5% have the CNTN4 mutated gene, both of which had high success rates so far in Phase 1 of the trial. They hope to have market approval by mid-2018.

Aevi Genomic Medicine will begin patient recruitment for AEVI-002 for treatment of pediatric Crohn’s Disease later this year as well.